Agenda

Time

DAY 1

Speaker/ moderator

12.00 - 13.00

Arrival, lunch and registration

 

13.00 - 13.10

Welcome

 

 

Opening lecture

Moderator: Mattias Linde

13.10 - 13.30

Anti-CGRP therapies: similar but not the same

Antoinette Maassen van den Brink

13.30 - 13.45

Discussion

 

 

 

Session 1
New treatments – Evaluation and management

Moderator: Messoud Ashina

13.45 - 13.30

When to evaluate effectiveness?- Anti-CGRPs and gepants

Erling Tronvik

14.00 - 14.15

When to switch? Anti-CGRPs and gepants

Bianca Raffaelli

14.15 - 14.35

Discussion

 

14.35 - 15.05

Break

 
 

Session 2
Controversies in migraine treatment

Moderator: Mattias Linde

15.05 - 15.15

Does vestibular migraine exist? Pro

Vlasta Vukovic Cvetkovic

15.15 - 15.25

Does vestibular migraine exist? Con

Jan Versijpt

15.25 - 15.45

Discussion

 

15.45 - 16.15

Break

 

16.15 - 16.30

Do we need drug holidays? Pro

Lars Bendtsen

16.30 - 16.45

Do we need drug holidays? Con

Tine Poole

16.45 - 17.15

Discussion

 

19.00

Dinner

 

DAY 2

9.00 - 9.05

Welcome to day 2

Tine Poole

 

 

Session 3
Rare types of migraine and their treatment

Moderator: Tine Poole

09.05 - 09.20

Trigeminal autonomic cephalalgias or migraine?

Anna Sundholm

09.20 - 09.35

TTH or CM or both? Multiple diagnosis

Aud Dueland

09.35 - 09.55

Discussion

 

09.55 - 10.15

Break

 

 

 

Session 4
Is there evidence…

Moderator: Messoud Ashina

10.15 - 10.25

for treating in the prodromal phase?

Koen Paemeleire

10.25 - 10.35

for using triptan during the aura phase?

Ville Artto

10.35 - 10.45

for neuroinflammation in migraine?

Rune Häckert

10.45 - 11.15

Discussion

 

11.15 - 11.35

Break

 
 

Session 5
The future of migraine management

Moderator: Mattias Linde

11.35 - 11.50

PACAP in migraine and cluster headache

Messoud Ashina

11.50 - 12.05

Swedish digi-physical headache center

Mattias Linde

12.05 - 12.30

Artificial intelligence in migraine management

Paolo Alonge

12.30 - 13.00

Discussion

 

13.00

Closure (Mattias Linde) and lunch

 

To Teva Denmark’s knowledge the meeting is in compliance with the rules of ENLI and will be reported to ENLI prior to the meeting.


All timings are CET.

The agenda is subject to change